Compounds containing polyethylene glycol (PEG), with an average molecular weight of 800 or more and a concentration of 30 mg / ml or more, are used to prevent and / or treat cancers on which the epidemic growth factor receptor depends.They are not carcinogens of squamous head and neck cells (hncc). Treatment and / or prevention of carcinogenesis in acute respiratory syndrome. 1. Characteristic 1: a component used to prevent and / or treat a subject's dependent anticancer substance, including polyethylene (PEG) with a concentration of 30 mg / ml or higher, wherein the average molecular weight (m695) of the substance is about 800 megatons or more. Claim 35: constituted in accordance with any of the above requirements prepared in the form of an aqueous solution or an aqueous solution, such as a mouthwash,Latex, toothpaste (e.g., toothpaste),Cream, such as lipstick,Ointment, foam, paint, sponge, gel, gum, aerosol, pill, trocisco, syrup (such as viscous syrup),Elector (linctus)Suspension, film (e.g. diving film)Compression agent (e.g. oral compression agent)4. Capsule (such as liquid capsule)；Film, ovarian compression coating, oral supplement Claim 37: composition consistent with any one of the 1 to 35 claims, including a therapeutic agent. Claim 38: the component of claim 37, namely, the therapeutic agent is an anticancer agent selected from anti EGFR, anti vegger, anti-igfr-1r, mTOR, platinum, taxano and folato anticancer agents.Composiciones que comprenden polietilenglicol (PEG) con un peso molecular medio ponderal de 800 o mayor y una concentración de 30 mg/ml o mayor, para usar en la prevención y/o tratamiento de cánceres dependientes del Receptor del Factor de Crecimiento Epidérmico (EGFR), que no son carcinoma de células escamosas de cabeza y cuello (HNSCC). Métodos para tratar y/o prevenir cánceres dependientes de EGFR. Reivindicación 1: Una composición para usar en la prevención y/o tratamiento de un cáncer dependiente de EGFR en un sujeto, la composición compre
